S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

LON:CLIN - Clinigen Group Share Price, Forecast & News

GBX 496.60
+16.90 (+3.52 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
480
Now: GBX 496.60
515
50-Day Range
357.80
MA: GBX 697.38
960.50
52-Week Range
350.40
Now: GBX 496.60
1,069
Volume524,891 shs
Average Volume432,646 shs
Market Capitalization£659.73 million
P/E Ratio47.75
Dividend Yield1.36%
BetaN/A
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More
Clinigen Group logo

Industry, Sector and Symbol

Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1283-495010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£491.70 million
Cash FlowGBX 30 per share
Book ValueGBX 332.40 per share

Profitability

Miscellaneous

Employees849
Market Cap£659.73 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter.


Clinigen Group (LON:CLIN) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLIN stock has decreased by 24.4% and is now trading at GBX 496.60. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clinigen Group.

How were Clinigen Group's earnings last quarter?

Clinigen Group PLC (LON:CLIN) posted its earnings results on Tuesday, February, 25th. The company reported $30.80 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $31.00 by $0.20. View Clinigen Group's earnings history.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group announced a dividend on Tuesday, February 25th. Investors of record on Thursday, March 19th will be paid a dividend of GBX 2.15 per share on Friday, April 17th. This represents a yield of 0.29%. The ex-dividend date is Thursday, March 19th. The official announcement can be viewed at this link. View Clinigen Group's dividend history.

What price target have analysts set for CLIN?

4 brokers have issued twelve-month price objectives for Clinigen Group's stock. Their forecasts range from GBX 790 to GBX 1,500. On average, they expect Clinigen Group's stock price to reach GBX 1,212.50 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View analysts' price targets for Clinigen Group.

Has Clinigen Group been receiving favorable news coverage?

Media headlines about CLIN stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clinigen Group earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutClinigen Group.

Who are some of Clinigen Group's key competitors?

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), Albemarle (ALB), RTI International Metals (RTI), NetApp (NTAP) and StatPro Group (SOG).

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
  • Mr. Nicholas Keher, CFO & Director
  • Ms. Debra Ainge, Chief Operating Officer
  • Matt Parrish, Head of Investor Relations
  • Mr. David Bryant, Director of Corp. Devel.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 496.60.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of £659.73 million and generates £491.70 million in revenue each year. Clinigen Group employs 849 workers across the globe. View additional information about Clinigen Group.

What is Clinigen Group's official website?

The official website for Clinigen Group is http://www.clinigengroup.com/.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.


MarketBeat Community Rating for Clinigen Group (LON CLIN)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  410 (Thanks for Voting!)
Underperform Votes:  115 (Thanks for Voting!)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel